Search for: "Pfizer Inc. v. Perrigo Co."
Results 1 - 19
of 19
Sorted by Relevance
|
Sort by Date
1 Dec 2009, 9:45 am
(patent infringement) 11/23: Pfizer, Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company and Warner-Lambert Company, LLC v. [read post]
3 Mar 2008, 9:27 pm
Pfizer, Inc. v. [read post]
18 Aug 2010, 12:19 am
King Pharmaceuticals, Inc. v. [read post]
16 Dec 2009, 3:39 am
Perrigo Co. et al. [read post]
2 Dec 2009, 4:31 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: World AIDS Day: Make it happen (Patent Baristas) (IP Watch) Venezuela to examine all pharmaceutical patents (IP tango) General World AIDS Day: Make it happen (Patent Baristas) (IP Watch) Biodiversity negotiations need to allow for flexibility in business, industry says (IP Watch) Brazilian government tailors a bill on trade… [read post]
28 Jul 2010, 12:06 am
K-V Pharmaceutical Co. et al. [read post]
7 Sep 2010, 6:10 pm
Highlights this week included: CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector) Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor) Aranesp (Darbepoetin) – EU: ECJ says ‘no’ to Kirin Amgen,… [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging… [read post]
17 Apr 2009, 12:00 am
Eli Lilly invalid (Patent Baristas), (Law 360) (Patent Docs) Gleevec / Glivec (Imatinib) – Novartis alpha crystalline form patent invalidated at pre – grant opposition (PatentCircle) Levaquin (Levofloxacin) - Daiichi Sankyo Co. [read post]
24 Feb 2010, 2:11 am
Co. v Doll (Filewrapper) US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs) US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs) US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’:… [read post]
24 Feb 2010, 2:11 am
Co. v Doll (Filewrapper) US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs) US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs) US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’:… [read post]
17 Feb 2010, 5:10 am
USA, Inc; Eli Lilly & Co. v. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still… [read post]
